209 related articles for article (PubMed ID: 33942287)
1. Current and emerging therapeutic approaches for T-cell acute lymphoblastic leukaemia.
Pocock R; Farah N; Richardson SE; Mansour MR
Br J Haematol; 2021 Jul; 194(1):28-43. PubMed ID: 33942287
[TBL] [Abstract][Full Text] [Related]
2. Improving nelarabine efficacy in T cell acute lymphoblastic leukemia by targeting aberrant PI3K/AKT/mTOR signaling pathway.
Lonetti A; Cappellini A; Bertaina A; Locatelli F; Pession A; Buontempo F; Evangelisti C; Evangelisti C; Orsini E; Zambonin L; Neri LM; Martelli AM; Chiarini F
J Hematol Oncol; 2016 Oct; 9(1):114. PubMed ID: 27776559
[TBL] [Abstract][Full Text] [Related]
3. Relapsed T Cell ALL: Current Approaches and New Directions.
McMahon CM; Luger SM
Curr Hematol Malig Rep; 2019 Apr; 14(2):83-93. PubMed ID: 30880359
[TBL] [Abstract][Full Text] [Related]
4. The New Therapeutic Strategies in Pediatric T-Cell Acute Lymphoblastic Leukemia.
Lato MW; Przysucha A; Grosman S; Zawitkowska J; Lejman M
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33925883
[TBL] [Abstract][Full Text] [Related]
5. Loss of oncogenic Notch1 with resistance to a PI3K inhibitor in T-cell leukaemia.
Dail M; Wong J; Lawrence J; O'Connor D; Nakitandwe J; Chen SC; Xu J; Lee LB; Akagi K; Li Q; Aster JC; Pear WS; Downing JR; Sampath D; Shannon K
Nature; 2014 Sep; 513(7519):512-6. PubMed ID: 25043004
[TBL] [Abstract][Full Text] [Related]
6. Relapsed/refractory early T-cell precursor acute lymphoblastic leukemia was salvaged by venetoclax plus HAG regimen.
Zhang X; Li J; Jin J; Yu W
Ann Hematol; 2020 Feb; 99(2):395-397. PubMed ID: 31879788
[No Abstract] [Full Text] [Related]
7. Targeted therapy and immunotherapy for T cell acute lymphoblastic leukemia/lymphoma.
Huang YH; Wan CL; Dai HP; Xue SL
Ann Hematol; 2023 Aug; 102(8):2001-2013. PubMed ID: 37227492
[TBL] [Abstract][Full Text] [Related]
8. The Genetics and Mechanisms of T-Cell Acute Lymphoblastic Leukemia.
Gianni F; Belver L; Ferrando A
Cold Spring Harb Perspect Med; 2020 Mar; 10(3):. PubMed ID: 31570389
[TBL] [Abstract][Full Text] [Related]
9. Investigational treatment options in phase I and phase II trials for relapsed or refractory acute lymphoblastic leukemia in pediatric patients.
Asare JM; Rabik CA; Muller B; Brown PA; Cooper S
Expert Opin Investig Drugs; 2021 Jun; 30(6):611-620. PubMed ID: 33896328
[No Abstract] [Full Text] [Related]
10. IL-7R is essential for leukemia-initiating cell activity of T-cell acute lymphoblastic leukemia.
González-García S; Mosquera M; Fuentes P; Palumbo T; Escudero A; Pérez-Martínez A; Ramírez M; Corcoran AE; Toribio ML
Blood; 2019 Dec; 134(24):2171-2182. PubMed ID: 31530562
[TBL] [Abstract][Full Text] [Related]
11. Venetoclax combined with decitabine and HAAG regimen: a novel salvage strategy for relapsed/refractory T-cell acute lymphoblastic leukaemia.
Zhu Y; Dai Y; Tang X
Ann Hematol; 2022 Nov; 101(11):2525-2528. PubMed ID: 36063200
[No Abstract] [Full Text] [Related]
12. Molecular pathogenesis and targeted therapies for NOTCH1-induced T-cell acute lymphoblastic leukemia.
Paganin M; Ferrando A
Blood Rev; 2011 Mar; 25(2):83-90. PubMed ID: 20965628
[TBL] [Abstract][Full Text] [Related]
13. Venetoclax and decitabine in refractory TP53-mutated early T-cell precursor acute lymphoblastic leukemia.
Kong J; Chen N; Li M; Zhang J; Wu X; Zong L; Wu D; Song B; Qiu H
Ann Hematol; 2022 Mar; 101(3):697-699. PubMed ID: 33954816
[No Abstract] [Full Text] [Related]
14. How I treat adults with relapsed or refractory Philadelphia chromosome-negative acute lymphoblastic leukemia.
Frey NV; Luger SM
Blood; 2015 Jul; 126(5):589-96. PubMed ID: 25966988
[TBL] [Abstract][Full Text] [Related]
15. Low-dose nivolumab-induced responses in acute lymphoblastic leukaemia relapse after allogeneic haematopoietic stem cell transplantation.
Chan TSY; Sim JPY; Kwong YL
Ann Hematol; 2017 Sep; 96(9):1569-1572. PubMed ID: 28573313
[No Abstract] [Full Text] [Related]
16. Emerging therapies in mantle cell lymphoma.
Hanel W; Epperla N
J Hematol Oncol; 2020 Jun; 13(1):79. PubMed ID: 32552760
[TBL] [Abstract][Full Text] [Related]
17. Investigating the response of paediatric leukaemia-propagating cells to BCL-2 inhibitors.
Diamanti P; Ede BC; Dace PE; Barendt WJ; Cox CV; Hancock JP; Moppett JP; Blair A
Br J Haematol; 2021 Feb; 192(3):577-588. PubMed ID: 32452017
[TBL] [Abstract][Full Text] [Related]
18. Recent advances in the treatment of acute lymphoblastic leukemia.
Rafei H; Kantarjian HM; Jabbour EJ
Leuk Lymphoma; 2019 Nov; 60(11):2606-2621. PubMed ID: 31092071
[TBL] [Abstract][Full Text] [Related]
19. FLT3 mutations in early T-cell precursor ALL characterize a stem cell like leukemia and imply the clinical use of tyrosine kinase inhibitors.
Neumann M; Coskun E; Fransecky L; Mochmann LH; Bartram I; Sartangi NF; Heesch S; Gökbuget N; Schwartz S; Brandts C; Schlee C; Haas R; Dührsen U; Griesshammer M; Döhner H; Ehninger G; Burmeister T; Blau O; Thiel E; Hoelzer D; Hofmann WK; Baldus CD
PLoS One; 2013; 8(1):e53190. PubMed ID: 23359050
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of venetoclax monotherapy in patients with relapsed, refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor therapy.
Eyre TA; Walter HS; Iyengar S; Follows G; Cross M; Fox CP; Hodson A; Coats J; Narat S; Morley N; Dyer MJS; Collins GP
Haematologica; 2019 Feb; 104(2):e68-e71. PubMed ID: 30190341
[No Abstract] [Full Text] [Related]
[Next] [New Search]
